Purchasing Tips: Glucagon x Insulina – Key Differences in Peptide Product Composition
Published: July 15, 2026 16:28
Author: Kathleen Hoffmann
Abstract: This analysis contrasts glucagon and insulin peptides, focusing on composition, purity, and stability. Market trends show rising demand for GLP-1 analogs, with insulin dominating diabetes care and glucagon for emergency hypoglycemia. Brand comparisons (e.g., Novo Nordisk vs. Eli Lilly) highlight differences in synthesis technology (recombinant vs. solid-phase) and certification (FDA, GMP). Key parameters include half-life, bioactivity, and impurity profiles. Selection tips emphasize verifying third-party lab reports, cold-chain logistics, and factory audits. Industry data projects 8.5% CAGR for peptide therapeutics, with glucagon niche applications expanding.